Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD

Neurology

Volumn 53, Issue 7, 1999, Pages 1425-1430

  Oliveri, R L ^a,b   Annesi, G ^b   Zappia, M ^a   Civitelli, D ^b   Montesanti, R ^a   Branca, D ^b   Nicoletti, G ^b   Spadafora, P ^b   Pasqua, A A ^b   Cittadella, R ^b   Andreoli, V ^b   Gambardella, A ^a,b   Aguglia, U ^a   Quattrone, A ^a,b,c  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b CNR   (Italy)

^c Policlinico Mater Domini   (Italy)

Author keywords

Dopamine D2 receptor gene; Dyskinesias; Gene polymorphism

Indexed keywords

DOPAMINE 2 RECEPTOR; LEVODOPA; ANTIPARKINSON AGENT;

ADULT; AGED; ALLELE; ARTICLE; DNA DETERMINATION; DOPAMINERGIC TRANSMISSION; DOSE RESPONSE; DRUG EFFECT; DRUG RECEPTOR BINDING; DYSKINESIA; FEMALE; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; RECEPTOR GENE; RISK ASSESSMENT; CASE CONTROL STUDY; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; TANDEM REPEAT;

ADULT; AGED; ALLELES; ANTIPARKINSON AGENTS; CASE-CONTROL STUDIES; DYSKINESIA, DRUG-INDUCED; DYSKINESIAS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; POLYMORPHISM, GENETIC; RECEPTORS, DOPAMINE D2; TANDEM REPEAT SEQUENCES;

EID: 0032589720     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.53.7.1425     Document Type: Article

References (40)

1. Nutt JG. Levodopa-induced dyskinesia: review, observations, and speculations. Neurology 1990;40:340-345.
2. Peppe A, Dambrosia JM, Chase TN. Risk factors for motor response complications in 1-dopa-treated parkinsonian patients. Adv Neurol 1993;60:698-702.
3. Caraceni T, Scigliano G, Musicco M. The occurrence of motor fluctuations in parkinsonian patients treated with long-term levodopa: role of early treatment and disease progression. Neurology 1991;41:380-384.
4. Blanchet PJ, Allard P, Grégoire L, Tardif F, Bédard PJ Risk factors for peak-dose dyskinesia in 100 levodopa-treated parkinsonian patients. Can J Neurol Sci 1996;23:189-193.
5. Miyawaki E, Lyons K, Pahwa R, et al. Motor complications of chronic levodopa therapy in Parkinson's disease. Clin Neuropharmacol 1997;20:523-530.
6. Hely MA, Morris JGL, Reid WGJ, et al. Age at onset: the major determinant of outcome in Parkinson's disease. Acta Neurol Scand 1995;92:455-463.
7. Kalow W. Pharmacogenetics in biological perspectives. Pharmacol Rev 1997;49:369-379.
8. Turjanski N, Lees AJ, Brooks DJ. In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias. Neurology 1997;49:717-723.
9. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
10. Quattrone A, Zappia M, Aguglia U, et al. The subacute levodopa test for evaluating long-duration response in Parkinson's disease. Ann Neurol 1995;38:389-395.
11. Zappia M, Colao R, Montesanti R, et al. Long-duration to levodopa influences the pharmacodynamics of short-duration response in Parkinson's disease. Ann Neurol 1997;42:245-249.
12. Zappia M, Montesanti R, Colao R, et al. Short-term levodopa test assessed by MT accurately predicts dopaminergic responsiveness in Parkinson's diseases. Mov Disord 1997;12:103-106.
13. Fahn S, Elton RL, the members of UPDRS development committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, eds. Recent developments in Parkinson's disease. London: MacMillan, 1987;153-163:
14. Munetz MR, Benjamin S. How to examine patients using the Abnormal Involuntary Movement Scale. Hosp Community Psychiatry 1988;39:1172-1177.
15. Folstein MF, Folstein SE, McHugh PR. "Mini Mental State Examination." A practical method for grading the cognitive state of patients for the clinicians. J Psychiatr Res 1975;12: 189-198.
16. Bech P. Rating scales for affective disorders. Their validity and consistency. Acta Psychiatr Scand 1981;64(suppl 295):1-101.
17. Cichon S, Nöthen MM, Erdmann J, Propping P. Detection of four polymorphic sites in the human D1 receptor gene (DRD1). Hum Mol Gen 1994;3:209.
18. Hauge X, Grandy D, Eubanks J, Evans G, Civelli O, Litt M. Detection and characterization of additional DNA polymorphisms in the dopamine D2 receptor gene. Genomics 1991;10: 527-530.
19. Bandmann O, Marsden CD, Wood NW. Genetic aspects of Parkinson's disease. Mov Disord 1998;13:203-211.
20. Nussbaum RL, Polymeropoulos MH. Genetics of Parkinson's disease. Hum Mol Genet 1997;6:1687-1691.
21. Payami H, Larsen K, Bernard S, Nutt J. Increased risk of Parkinson's disease in parents and siblings of patients. Ann Neurol 1994;36:659-661.
22. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the α-sinuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-2047.
23. Gasser T, Muller-Myhsok B, Wszolek ZK, et al. A susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nat Genet 1998;18:262-265.
24. Tsuenoka Y, Matsuo Y, Iwahashi K, Takeuchi H, Ichiwaka Y. A novel cytochrome P-450 2D6 mutant gene associated with Parkinson's disease. J Biochem 1993;114:263-266.
25. Le Couter DG, Leighton PW, McCann SJ, Pond S. Association of a polymorphism in the dopamine-transporter gene with Parkinson's disease. Mov Disord 1997;12:760-763.
26. Costa P, Checkoway H, Levy D, et al. Association of a polymorphism in intron 13 of the monoamine oxidase B gene with Parkinson's disease. Am J Med Genet 1997;74:154-156.
27. Kobayashi T, Matsumine H, Matuda S, Mizuno Y. Association between the gene encoding the E2 subunit of the α-ketoglutarate dehydrogenase complex and Parkinson's disease. Ann Neurol 1998;43:120-123.
28. Nanko S, Ueki A, Hattori M, et al. No allelic association between Parkinson's disease and dopamine D2, D3, and D4 receptor gene polymorphisms. Am J Med Genet 1994;54:361-364.
29. Planté-Bordeneuve V, Taussig D, Thomas F, et al. Evaluation of four candidate genes encoding proteins of the dopamine pathway in familial and sporadic Parkinson's disease: evidence for association of a DRD2 allele. Neurology 1997;48: 1589-1593.
30. Cardoso F, Jankovic J. Dystonia and dyskinesia. Psychiatric Clin North Am 1997;20:821-838.
31. Luquin MR, Scipioni MR, Vaamonde J, Gershanik O, Obeso JA. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. Mov Disord 1997; 7:117-124.
32. Marconi R, Lefebvre-Caparros D, Bonnet A, Vidailhet M, Dubois B, Agid Y. Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology. Mov Disord 1994;9:2-12.
33. Mouradian MM, Heuser IJE, Baronti F, Fabbrini G, Juncos JL, Chase TN. Pathogenesis of dyskinesias in Parkinson's disease. Ann Neurol, 1989;25:523-526.
34. Wu RM, Chiu HC, Wang M, Chen RC. Risk factors on the occurrence of response fluctuations and dyskinesias in Parkinson's disease. J Neural Transm Park Dis Dement Sect 1993;5: 127-133.
35. Muscettola G, Pampallona S, Barbato G, Casiello M, Bollini P. Persistent tardive dyskinesia: demographic and pharmacological risk factors. Acta Psychiatr Scand 1993;87:29-36.
36. Rosengarten H, Schweitzer JW, Friedhoff AJ. A mechanism underlying neuroleptic induced oral dyskinesias in rats. Pol J Pharmacol 1993;45:391-398.
37. Chen CH, Wei FC, Koong FJ, Hsiao KJ Association of TaqI. A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia. Biol Psychiatry 1997;41:827-829.
38. Steen VM, Lovlie R, MacEwan T, McCreadie RG. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol Psychiatry 1997;2:139-145.
39. Altshusler D, Kruglyak L, Lander E. Genetic polymorphisms and disease. N Engl J Med 1998;338:1626.
40. Castiglione CM, Deinard AS, Speed WC, et al. Evolution of haplotypes at the DRD2 locus. Am J Hum Genet 1995;57: 1445-1456.